We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HealthEquity (HQY) Enhances Commuter Offering With New Buyout
Read MoreHide Full Article
HealthEquity, Inc. (HQY - Free Report) recently acquired Luum — a thriving technology platform that helps employers manage commute benefits for its employees. The acquisition is likely to boost HealthEquity’s commuter offering. Notably, the terms of the deal were kept under wraps.
For investor’s note, Luum, which was founded in 2012, provides safe, sustainable and flexible mobility options to employees, thereby helping companies to make their workplaces more dynamic.
The acquisition will bolster HealthEquity’s, renowned for being the nation’s largest independent health savings account (“HSA”) custodian, commuter providing and generate new potential to hybrid-workplace strategies.
Significance of the Acquisition
The acquisition will bolster HealthEquity’s commuter offering by providing a vital toolset that an administration requires to execute flexible return-to-office and hybrid-workplace strategies.
HealthEquity will leverage Luum’s advanced technology platform by pairing it with HR and Payroll systems that will enable it to offer safe, inexpensive commute alternatives and flexible remote-work benefits.
HealthEquity will contribute to corporate sustainability as well with the implementation of hybrid workplace strategy through measurement of substantial effect on climate and other environmental conservation areas.
Industry Prospects
Per a report by Market Research Future, the global smart workplace is anticipated to witness a CAGR of 13% and is expected to reach $47 Billion by 2023. Increasing demand for smart office solutions, emergence of smart cities and growing demand for smart networks for energy efficiency are fueling growth in the market.
Considering market growth, implementation of hybrid-work strategies is an appropriate move by HealthEquity to improve their workforce efficiency, which will foster business growth.
Price Performance
Shares of the company have gained 52% in a year’s time compared with the industry’s growth of 29.7%.
Zacks Rank and Key Picks
Currently, HealthEquity carries a Zacks Rank #3 (Hold).
BIOMERIEUX has a projected long-term earnings growth rate of 24%.
Harrow Health has a projected long-term earnings growth rate of 90%.
Healthways has an estimated long-term earnings growth rate of 10%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
HealthEquity (HQY) Enhances Commuter Offering With New Buyout
HealthEquity, Inc. (HQY - Free Report) recently acquired Luum — a thriving technology platform that helps employers manage commute benefits for its employees. The acquisition is likely to boost HealthEquity’s commuter offering. Notably, the terms of the deal were kept under wraps.
For investor’s note, Luum, which was founded in 2012, provides safe, sustainable and flexible mobility options to employees, thereby helping companies to make their workplaces more dynamic.
The acquisition will bolster HealthEquity’s, renowned for being the nation’s largest independent health savings account (“HSA”) custodian, commuter providing and generate new potential to hybrid-workplace strategies.
Significance of the Acquisition
The acquisition will bolster HealthEquity’s commuter offering by providing a vital toolset that an administration requires to execute flexible return-to-office and hybrid-workplace strategies.
HealthEquity will leverage Luum’s advanced technology platform by pairing it with HR and Payroll systems that will enable it to offer safe, inexpensive commute alternatives and flexible remote-work benefits.
HealthEquity will contribute to corporate sustainability as well with the implementation of hybrid workplace strategy through measurement of substantial effect on climate and other environmental conservation areas.
Industry Prospects
Per a report by Market Research Future, the global smart workplace is anticipated to witness a CAGR of 13% and is expected to reach $47 Billion by 2023. Increasing demand for smart office solutions, emergence of smart cities and growing demand for smart networks for energy efficiency are fueling growth in the market.
Considering market growth, implementation of hybrid-work strategies is an appropriate move by HealthEquity to improve their workforce efficiency, which will foster business growth.
Price Performance
Shares of the company have gained 52% in a year’s time compared with the industry’s growth of 29.7%.
Zacks Rank and Key Picks
Currently, HealthEquity carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are BIOMERIEUX (BMXMF - Free Report) , Harrow Health, Inc. (HROW - Free Report) and Healthways, Inc. , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
BIOMERIEUX has a projected long-term earnings growth rate of 24%.
Harrow Health has a projected long-term earnings growth rate of 90%.
Healthways has an estimated long-term earnings growth rate of 10%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>